20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

The Essential Guide to Poloxamer 407: A Key Pharmaceutical Excipient from NINGBO INNO PHARMCHEM CO.,LTD.

NINGBO INNO PHARMCHEM CO.,LTD. is pleased to present a detailed look at Poloxamer 407, a vital pharmaceutical excipient that plays a critical role in drug formulation and delivery. As a non-ionic surfactant and a triblock copolymer of ethylene oxide and propylene oxide, Poloxamer 407 offers a unique set of properties that address various formulation challenges.

The primary function of Poloxamer 407 as a poloxamer 407 solubilization agent is key to its widespread use. Many active pharmaceutical ingredients (APIs) have limited solubility in aqueous environments, hindering their absorption and efficacy. By incorporating Poloxamer 407, formulators can significantly enhance the solubility of these compounds. This is why it's essential to buy Poloxamer 407 for pharma applications where consistent and effective solubilization is required.

The distinctive poloxamer 407 thermoreversible gel characteristic is another significant advantage. This property allows for the creation of temperature-responsive formulations. For instance, solutions can be designed to gel at body temperature, facilitating sustained or targeted drug release. Understanding these poloxamer 407 API properties is crucial for developing advanced drug delivery systems that improve patient outcomes.

NINGBO INNO PHARMCHEM CO.,LTD. emphasizes the importance of sourcing high-quality Poloxamer 407. Ensuring consistent purity and adherence to pharmacopeial standards is vital. By partnering with a reputable poloxamer 407 supplier quality, pharmaceutical companies can guarantee the safety, efficacy, and stability of their products. The broad range of poloxamer 407 uses in medicine highlights its indispensability across various therapeutic areas.

Exploring the comprehensive poloxamer 407 formulation benefits reveals its power in creating innovative and patient-centric pharmaceutical products. From improving the delivery of poorly soluble drugs to enabling advanced controlled-release systems, Poloxamer 407 is a versatile excipient that NINGBO INNO PHARMCHEM CO.,LTD. is proud to supply.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Innovating with Poloxamer 407: From Excipient to Enabling Technology in Pharmaceuticals

Next: Understanding Ceritinib: A Deeper Look at its Role in Treating ALK-Positive Lung Cancer

All Rights Reserved